Since the introduction of extracorporeal hemodialysis for the management of renal failure, its usefulness in the treatment of otherwise fatal poisoning by various chemical agents has been repeatedly demonstrated. Among these agents have been various barbiturates,' salicylates,' and bromide.' Recent experience with a case of intoxication with ethynyl-cyclohexyl carbamate ( Fig. 1) , a short-acting nonbarbiturate hypnotic,' provided an opportunity to demonstrate its dialyzability. Although the poisoning proved fatal in this instance, the ability to remove an appreciable quantity of the drug by hemodialysis suggests that patients with severe intoxication coming under observation earlier may be treated by this method more successfully. CASE 
HISTORY

M.F.K., NCMH Unit No. 05-26-69
A 24-year-old single white female graduate student was brought to the Emergency Ward of the North Carolina Memorial Hospital at 9:30 p.m. on 9/25/58. She had been found comatose in her apartment shortly before with the beginning of a "suicide note" and an empty prescription bottle discovered near her body. The prescription had been refilled one week previously after a long interval for at least thirty 0.5 gram tablets of ethynyl-cyclohexyl-carbamate (ValmidR, Lilly). The patient was last heard from specifically 26 hours prior to the discovery prompted by her having missed several specific appointments throughout the day. Past medical history, obtained from friends and previous medical record, was noncontributory. There was no personal history of diabetes, epilepsy, trauma, syncope, cardiac, pulmonary or renal disease. Family history was also noncontributory.
Extracorporeal hemodialysis I DAVIS, BLYTHE, NEWTON, WELT Physical examination showed a well-developed, well-nourished white female, comatose and cyanotic. There was no evidence of vomiting. Respirations were shallow at 24/minute. The blood pressure and pulse were unobtainable. Temperature was 95.40 F., p.r. Hydration was fair. External examination revealed a 6x6 inch pressure point over the right hip, suggesting that the patient had lain on that side for a long period. There was no evidence of trauma to the head or the rest of the body, nor was there sign of fracture. The pupils were normal in size with the left pupil slightly larger than the right; there was no pupillary response to light. Ear, nose, and throat were normal. heard bilaterally in the chest; these were cleared considerably on suction. The heart was normal in size and showed a normal sinus rhythm at a rate of 78. The aortic and pulmonary second heart sounds were equal in intensity and there were no murmurs. 45 . Because of the demonstration of an acetylenic compound in an ether extract of the dialysate on qualitative test with alkaline ammoniacal silver solution (a control test with commercial ethinamate was also positive), it was decided to centinue the dialysis for another six hours. At the end of this period the arterial blood C02 content had risen to 10.1 without significant change in other chemical studies, except for the aforementioned fall in blood sugar to 144 mg.o. At this point, after 12 hours of hemodialysis, the patient developed pulmonary edema and expired. Post-mortem examination showed pneumonia, multiple pulmonary emboli with infarction, hepatic and splenic congestion, and bilateral cortical necrosis of the kidneys.
DISCUSSION
Ethynyl-cyclohexyl carbamate (ethinamate, ValmidR Lilly) is a shortacting nonbarbiturate hypnotic drug with a short duration of action.8"' 5.9 The therapeutic dose is considered to be very much less than the toxic dose, but little has been done to elucidate its pharmacology. One patient is reported to have taken 28 gm. of the medication without fatal outcome.' No antidote is known. The kidney plays no role in the metabolic transformation of ethinamate while data on the role of the liver are contradictory."'
The metabolic fate of ethinamate in rats has recently been clarified by McMahon.' Seventy-three per cent of a 50 mg./Kg. intraperitoneal dose (labeled with C-14 on the carbonyl group) was eliminated within eight hours, 10 per cent as respiratory CO2 and 63 per cent in the urine as unchanged ethinamate and some metabolite of the drug. The metabolite was identified by paper chromatography and subjection to the action of B8-glucuronidase as mainly hydroxy-ethinamate and its 83-glucuronide in approximately equal amounts. Of the urinary excretory products, 2 per cent was unchanged ethinamate, 89 per cent hydroxy-ethinamate and 9 per cent unidentified metabolites. The acetylenic group remained unchanged by the body. Whether hydroxy-ethinamate has any hypnotic effect has not been reported.
There are many unexplained features in the course of the patient reported above. The rapid onset of a very severe acidosis without ketosis and clinically not resembling diabetic acidosis despite the elevated blood sugar (possibly attributable to norepinephrine administration) remains unexplained. A test of a normal urine specimen to which a small amount of ethinamate had been added showed only a trace reaction to ClinitestR tablet and a negative reaction to glucose oxidase impregnated urinary test paper, suggesting that the ethinamate alone could not account for the elevated sugar. While the hyponatremia could be explained on the basis of the elevated blood sugar, the marked elevation of the hematocrit remains mysterious in the face of the absence of evidence of significant dehydration. Possible shifts of fluid internally out of the plasma may account for this, but the stimulus and mechanism for this shift are unrecognized here.
Hemodialysis was undertaken because of the lack of progress of the patient already moribund and in cardiovascular collapse, in the hope that the drug would prove dialyzable. The dialysates from the two six-hour runs on the artificial kidney were very kindly analysed by Dr. John S. Welles (The Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana) by a chromatographic technique. The total amount of ethinamate and hydroxy-ethinamate removed is indicated in Table 1: Although only 1.23 gm. of ethinamate are accounted for on the two dialyses, hemodialysis was not begun until an estimated 40-44 hours following the ingestion of the medication, whose action and stay in the body are known to be short. The amount removed may, in this light, be significant. For this reason, then, the demonstration of the dialyzability of ethinamate and its metabolic product appeared worthy of a report in the hope that cases of severe intoxication appearing earlier in their course may have a more favorable outcome. The appearance of a quantity of the drug in the second six-hour dialysate equal to the amount in the first dialysate may not be a reflection of poor dialyzability from the blood but may, rather, indicate an intracellular location across a membrane of limited permeability to the drug. The effect of the patient's extreme mixed metabolic and respiratory acidosis on this permeability is conjectural. In the absence of plasma level determinations, the gradient and effect of protein binding cannot be evaluated. The need for prolonged or repeated hemodialysis in cases of ethinamate intoxication should therefore be anticipated.
SUMMARY
A fatal case of ethinamate intoxication is reported. The patient was treated by hemodialysis unsuccessfully, but the demonstration of significant amounts of ethinamate and its metabolic product in the dialysate warrants an early trial of this mode of therapy in other severe cases of ethinamate intoxication unresponsive to other measures.
